Saturday, October 31, 2026

CBOE Slides By 5% In The Last 10 Sessions

CBOE Slides By 5% In The Last 10 Sessions

(VIANEWS) - CBOE (VIX) has been up by 5.53% for the last 10 sessions. At 07:10 EST on Wednesday, 27 March, CBOE (VIX) is $12.99.

Concerning CBOE's yearly highs and lows, it's 0% down from its 52-week low and 62.94% down from its 52-week high.

Volatility

CBOE's last week, last month's, and last quarter's current intraday variation average was a positive 0.38%, a negative 0.08%, and a positive 3.41%, respectively.

CBOE's highest amplitude of average volatility was 0.85% (last week), 2.69% (last month), and 3.41% (last quarter), respectively.

Index Price Classification

According to the stochastic oscillator, a useful indicator of overbought and oversold conditions, CBOE's is considered to be oversold (<=20).

News about

  • According to Zacks on Monday, 25 March, "The three major stock indexes - the Dow, the S&P 500 and the Nasdaq Composite - have put impressive performances this year. ", "Capital Economics predicted that the S&P 500 could reach 6,500 by 2025-end if the ongoing euphoria surrounding artificial intelligence (AI), especially generative AI, continues. "
  • According to Zacks on Monday, 25 March, "In that same time, the Computer and Technology sector gained 3.86%, while the S&P 500 gained 3.05%."
  • According to Zacks on Monday, 25 March, "Yet, the global investment management giant projected its bull case for the S&P 500 at 6,000 by the end of this year, depending on the performances of mega-cap techs.", "Recently, The Goldman Sachs Group Inc. ((GS Quick QuoteGS - Free Report) stuck to its year-end 2024 S&P 500 forecast at 5,200. "
  • According to Zacks on Monday, 25 March, "View all Key Company Metrics for Oxford Industries here>>>Over the past month, shares of Oxford Industries have returned +9.7% versus the Zacks S&P 500 composite's +3.1% change. "
  • According to Zacks on Monday, 25 March, "The Dow and the S&P 500 closed in the red but the Nasdaq finished in positive territory."

More news about CBOE (VIX).

ViaNews Editorial Team

Via News Editorial Team delivers comprehensive financial news coverage and market analysis from journalists around the world. Our team specializes in data journalism and in-depth reporting on stock markets, business developments, and economic trends.

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
ESMO 2026 Oncology Data Wave Builds Toward Ivonescimab PDUFA, While Micro-Cap Biotech Exits the Market
Late October 2026 is a dense catalyst window led by ESMO 2026. Daiichi Sankyo's DXd antibody-drug conjugate (ADC) programs (DESTINY-Lung04, DESTINY-Breast11, REJOICE-Ovarian01/02, TUXEDO-3), Guardant's 25 abstracts and the PACE-LUNG ctDNA trial all report there. These feed into the FDA's 14 November 2026 PDUFA date for ivonescimab. Large and mid-cap developers with late-stage data and commercial launches (ZEGFROVY, ANKTIVA, MIUDELLA, lorundrostat, duvakitug) are drawing capital and attention. Spago Nanomedical's board decision to seek a Nasdaq First North delisting (EGM 19 November, application 25 January 2027) shows the capital squeeze on early-stage, single-asset names (Tumorad is Phase I).
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
Ford Motor Company
Both facts give cash for Ford Motor Company at the same point in time (2025-12-31; FY 2025 year-end and Q4 2025 year-end are the same date). Both are labelled USD, but the values are 23,356,000,000 and 23.356, which cannot both be true in USD. The two numbers agree once the second is read as billions (23.356 bn = 23,356,000,000), so the economic content is consistent and the conflict is a unit/scale error in the Q4 2025 record. The period is not the reason for the conflict: a Q4 and an FY figure at the same year-end date should match.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,994
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,994 facts checked against source5,514 source documents archived
Query this data → isubstrate.com